Immune Response, Detection of IgE and PGE2 during Vaginal Candidiasis in Mice

^{1,2}Rosymar Coutinho Lucas, ³Rafael Taglialegna, ^{4,5}Carolina Nunes França, ⁶Fernando Segato, ⁷Rodrigo A. Cazzaniga, ³Carol K. Da Fonseca and ²Claudia M.L. Maffei

¹Department of Biochemistry, University of Sao Paulo, SP, Brazil

²Department of Biology, University of Sao Paulo, SP, Brazil

³Department of Cellular and Molecular Biology and Pathogenic Bioagents, University of Sao Paulo, SP, Brazil

⁴*Health Science Post Graduation, University of Santo Amaro, Brazil*

⁵Department of Medicine, Federal University of Sao Paulo, Brazil

⁶Department of Biotechnology, Lorena School of Engineering, University of Sao Paulo, SP, Brazil

⁷Department of Morphology, Federal University of Sergipe, SE, Brazil

Article history Received: 05-12-2015 Revised: 12-07-2016 Accepted: 13-07-2016

Corresponding Author: Rosymar Coutinho Lucas Department of Biochemistry, University of Sao Paulo, SP, Brazil Fax: +55 16 36023229 Email: rosymar_lucas@hotmail.com Abstract: Vulvovaginal candidiasis is an opportunistic infection that affects most women in adult life, but the defense mechanism remains to be elucidated. Animals treated with estradiol were inoculated with Candida albicans having high virulence power. The experimental control consisted of animal groups treated with estradiol and animals without treatment that were inoculated with physiologic serum. The vaginal wall was collected, at different times. The material was destined to the counting of Colony Forming Units (CFU), detection of PGE2, IgE and histological staining (hematoxylin and eosin, silver and toluidine blue) for the study of the infected vaginal section. Experimental infection was predominant due to hyphae and pseudohyphae parasitism, involving the keratinized layer of the vaginal stratified squamous epithelium, without compromise submucosal or muscular layer. Furthermore, it was observed mast and polymorphonuclear cells on vaginal tissue in response to the infection. On the other hand, IgE and PGE2 participated in the response to experimental C. albicans vaginal infection. The raise in these mediators matches with the load fungal increase during the infection evolution and with the presence of mast cell. These results suggest a probable atopic component involved in the vaginal candidiasis pathogenesis.

Keywords: Immune Response, Vulvovaginal Candidiasis, Candida albicans, Mast Cell

Introduction

Candida albicans (C. albicans) is a pleomorphic fungus showing yeast, pseudohyphae and hyphae forms according to the environmental conditions (e.g., temperature and pH variation). This fungus is a diploid organism without meiosis division and its teleomorphic state has not been described yet (Bennett and Johnson, 2005). The host tissue invasion is mainly due to *C. albicans* plasticity and production of adhesion factors and extracellular proteolytic enzymes, factors which help its virulence power (McCullough *et al.*, 1996). *C. albicans* is the most important causative agent in 85-90% of Vulvovaginal Candidiasis (VVC) symptomatic cases.

VVC is an opportunistic infection that affects 75% of women during their reproductive life and about 5% of them will develop Recurrent Vulvovaginal Candidiasis (RVVC) (Fidel *et al.*, 1995; Carrara *et al.*, 2010; Harriott *et al.*, 2010; Yano *et al.*, 2012). The mechanism of defense used by the host against this fungus is related to an activity of innate and adaptive immune response (Yano *et al.*, 2012). However, the exact knowledge on how the putative immune system mechanisms of the female genital treatment react against this yeast is still unclear. Some evidences have shown the involvement of IgE and PGE2 production and also the histamine releasing by mast cells in the disease pathogenesis, but the cellular types involved in the immune response are



© 2016 Rosymar Coutinho Lucas, Rafael Taglialegna, Carolina Nunes França, Fernando Segato, Rodrigo A. Cazzaniga, Carol K. Da Fonseca and Claudia M.L. Maffei. This open access article is distributed under a Creative Commons Attribution (CC-BY) 3.0 license. not totally clear (Witikin *et al.*, 1988; Noverr *et al.*, 2001; 2002; Erb-Downward and Noverr, 2007).

Several incidences of VVC and the emergence of RVVC, after antifungal agent treatments, stimulate the researches to elucidate the mechanisms involved in *C. albicans* pathogenicity and the vaginal immunological response pattern. Thus, the aims of this investigation were to evaluate the patterns involved in cell immunological response (mast cell and neutrophils) as well as to investigate the release of IgE and PGE2 during the murine vaginal candidiasis evolution.

Experimental Procedures

This research is an experimental study that was performed at Faculdade de Medicina de Ribeirão Preto-USP (FMRP-USP). It was conducted according to ethical principles and started after the project had been approved by the Ethics Committee on Animal Experiments (CETEA) of that institution.

Candida Albicans Sample

C. albicans strains were isolated from patients with fungemia that were being treated at Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP). The isolates were stored in sterile distilled water and stocked at the Fungi Collection of Medical Mycology Laboratory, Department of Cell Biology, Molecular and Pathogenic (FMRP-USP). The Bioagents microorganism identification was performed using standard methods for C. albicans characterization, such as: Germ tube formation in fetal bovine serum at 37°C, chlamydospores formation on corn meal-agar medium and auxanogram test. In order to perform this research, the strain that demonstrated high virulence aspect was chosen, parameter evaluated by phospholipase and proteinase activity measurement (Lacaz, 2002).

Inoculums Preparation and Experimental Infection

C. albicans was grown in Sabouraud dextrose agar with 50 mg L⁻¹ chloramphenicol (SDAC) at 35°C for 24 h. A fresh colony was then transferred to 5 mL of liquid medium and incubated at 35°C for 48 h in a shaker, followed by centrifugation at 2000 rpm for 15 min. The pellet was washed three times with sterile saline solution and then, resuspended in 1 mL of the same solution for counting cells in a Neubauer chamber. The inoculum solution was prepared in a concentration of 1.5×10^6 cells mL⁻¹ and serial dilutions were plated on SDAC to determine the inoculums viability.

Three days before the experimental infection, 186 BALB/c females mice 7-9 weeks old, obtained from FMRP/USP vivarium, were subcutaneously treated with 0.02 mg estradiol valerate, diluted in 0.1 mL castor oil

heated to 37°C. This treatment causes changes in the thickness and keratinization of the vaginal epithelium, providing a substrate for attachment, growth and formation of a biofilm by the fungus and optimizes the experimental infection conditions (Cassone et al., 2007). Mice were intravaginally inoculated with C. albicans (1.5×10^6 cells/20 µL in saline solution), using a blunt needle. Experimental control consisted of treated and non-treated groups with estradiol valerate, non-inoculated with the yeast, but with saline solution. Vaginal walls from the animals were submitted to counting of the colony-forming units, determination of local cellular immune response (mast and polymorphonuclear cells) and dosage of IgE/PGE2 in vaginal tissue during the course of vaginal infection by C. albicans..

Experimental Groups

Three experimental groups were evaluated at the following times: 4, 24, 48 and 192 h.

The right lateral vaginal wall was processed using an Ultra Turrax® T18 basic IKA® homogenizer (Cole Parmer-USA) for the first experimental group, aiming to determine the number of viable yeast cell during the infection course. The left lateral vaginal wall was fixed in 10% formaldehyde for the histopathological studies by the hematoxylin/eosin, Gomori Trichrome (Gomori, 1950) and toluidine blue staining.

The second group was perfused with 25 mL Phosphate Buffer (PBS) at 4°C to remove circulating blood cells from the vaginal mucosa. Vaginal wall was kept in saline solution for mechanical tissue grinding using an Ultra Turrax® T18 basic IKA® homogenizer (Cole Parmer-USA). The obtained suspension was stored at -70°C, for subsequent PGE and IgE quantification by ELISA.

The last experimental group had the vaginal tissue collected, immersed and fixed in 2.5% glutaraldehyde for electron microscopy analysis after the infection process.

Vaginal Mucosal Yeast Quantification

Vaginal wall from the infected animals was weighed and homogenized into tubes with 1.0 mL sterile saline solution with penicillin (100 U mL⁻¹) and streptomycin (100 mg mL⁻¹). The harvested homogenate was used to prepare the serial dilutions (1:10, 1:100, 1:1000), which were plated on ASDC for viable cells determination. Plates were incubated at 35°C for 48 h and Colony-Forming Units (CFU) were quantified. Results were expressed as the CFU log average of five animals per infection time studied by the formula:

Log $10 = [CFU \text{ average} \times (dilution \times 2) \times (X + organ weight)]$ X = Solution volume used for grinding the organ

Histopathological Analysis of Infected Vaginal Tissue

Vaginal wall was fixed in 10% formalin and 10 μ m thick histological sections were stained with hematoxylin/eosin and Gomori Trichrome (Gomori, 1950) for histopathological studies, during all the course of infection. The analysis was performed in optical microscope Olympus at 100 and 400× magnification followed by photo documentation.

Scanning Electron Microscopy (SEM)

Vaginal tissues were collected and immersed in 2.5% glutaraldehyde, for 3 h for the fixation. Then the tissue was washed three times with 0.1 M phosphate buffer for 5 min and post-fixated in phosphate buffered solution with 1% osmium tetroxide. A new wash was performed with phosphate buffer solution. This material was dehydrated in acetone 30, 50, 70, 90 and 95% for 15 min in each step and then in 100% acetone, three times for 20 min. In the next step, the material infiltration was performed in resin/acetone (v:v), for 48 h under stirring. The material was transferred to pure resin (Araldite 6005), for 2 h at 45°C, immersed in silicone containers properly oriented and followed by the resin polymerization for 72 h at 60°C. Samples were processed on Bal-Tec CPD 030 equipment to obtain the critical point. Vaginal tissue assembly was done in special supports that allow the electron conduction. The last step was the gold rinsing in the Bal-Tec SCD 050 equipment. Analysis of all samples was performed in a scanning electron microscope (JEOL JSM 5200 scanning microscope).

Mast Cells Detection using Toluidine Blue

Vaginal tissue was de-waxed in xylol1 and xylol2 for 3 min. Then, the sections were hydrated in: Alcoholxylene, absolute alcohol and alcohol 95, 90, 80, 70 and 50%, for 2 min and washed with water. The slides were stained with 0.1% toluidine blue at pH 2.8 for 20 min and dehydrated in 90% ethanol, 95 and 100%, absolute ethanol-xylol, xylol1 and xylol 2 for 3 min. Analyses were performed in optical microscope.

Prostaglandin E2 Detection and Quantification

Homogenized tissues stored in 0.85% saline solution at -70°C were treated with 1N HCl and centrifuged at 2000 rpm up to the solubilization. Then, these materials were purified on columns (Sep-Pak ® Cartridges) to separate the lipid components and aliquots of 50 μ L of each treated sample were transferred into 96-well plates (Prostaglandin E₂ direct Biotrak Assay Kit-GE Healthcare Life Science), which already had the primary antibody (anti-goat IgG mouse). Each well was covered with 50 μ L of secondary anti-PGE2 and 50 μ L of the secondary antibody conjugated to peroxidase. The plate was incubated for 1 h under stirring in light privation. After this procedure, the plates were washed with washing buffer from the kit and 150 μ L well⁻¹ of development solution was added, followed by the incubation for 30 min. The reaction was stopped by adding 100 μ L well⁻¹ of 1M sulfuric acid and the results were obtained in an ELISA reader at 450 nm. Sample quantifications were evaluated according to the standard curve from the Kit. The results were expressed as the average measurements obtained in two experiments, five animals for each infection time.

Detection of IgE

IgE detection was performed with ELISA assay using 100 μ L of homogenized samples stored in 0.85% saline without dilution and transferred to 96-well plates (Corning Costar® Incorporated). Each well was covered with 100 μ L IgE capture primary antibody (BD Biosciences) (2 mg mL⁻¹) and the plate was incubated overnight at 4°C. The next step was nonspecific sites blocking using 200 μ L PBS with 1% BSA for 1 h, follow by washing with PBS containing 0.05% Tween 20. All samples were incubated with the biotinylated anti-mouse IgE secondary antibody (BD Biosciences) (4 mg mL⁻¹) for 1 h and washed one more time.

Finally, it was added 100 μ L well⁻¹ of avid inhorseradish peroxidase complex (BD Biosciences) diluted in blocking buffer (1:1000) for 30 min in light privacy. The reaction was developed with 100 μ L well⁻¹ Tetramethylbenzidine (TMB) for 10 min and stopped by adding 100 μ L of sulfuric acid 1 M per well. Results were obtained on ELISA reader at 450 nm.

Statistical Analysis

The normal distribution of the studied samples was performed by the Shapiro-Wilk test and for the comparison among them the one-way analysis of variance was applied. Graph Pad Prism® 3.0 (CA, EUA) software was used. The statistical significance was accepted at p<0.05.

Results

The efficiency of the murine infection by *C. albicans* was demonstrated by some parameters. The UFC counting demonstrated that all evaluated groups presented increasing levels of infection according to the infection evolution (data not shown). After 24 h, there was the prevalence of parasitism under the pseudohyphae form, with growth of infectious cells in the epithelial layer without invasion in deep layers. These results were confirmed by hematoxylin and eosin staining, specific fungi staining, the Gomori Trichrome (Gomori, 1950) and also, by scanning electronic microscopy (Fig. 1).

Figure 2 shows the typical presence of a polymorphonuclear cells (PMN) microabscess in the mucosal layer.



Fig. 1. Surface parasitism of mice vaginal mucosa after 48 h post-infection by *C. albicans*. Hematoxylin-eosin (A) and Gomori -Methanamine/Silver (GMS). Barr: 50 μm. (B) showing numerous pseudohyphae nonadherent. Barr: 250 μm. Scanning electron microscopy (C), showing the stratified Epithelium (Ep) and pseudohyphae free (Arrow), 3500× magnification



Fig. 2. Polymorphonuclear microabscess cells in mice mucosal surface infected with *Candida albicans* after 120 h A and B; C and D = uninfected controls untreated and E and F = controls treated with 0.02 mg of estrogen, respectively showing absence of polymorphonuclear microabscess (Arrow). Barr: 50 μm

Mast cells could be visualized in all infection times, evidenced by wine staining due to the metachromasia phenomenon, with an increase of these cells at further infection times, which corresponded to the infection response (Fig. 3).

In the first infection times, PGE2 dosages were observed in quite elevated levels compared to the noninfected controls. After 48 h, there was a PGE2 pick and a new exacerbation in 192 h, which corresponded, to yeasts increase and pseudohyphae presence, in the histopathological sections (Fig. 4).

IgE dosage elevation in the vaginal tissue was observed after 48 h of infection remained elevated in the subsequent time, which was coincident with mast cell degranulation detection in the vaginal mucous membrane (Fig. 5).

Discussion

The pleomorphic *C. albicans* yeast lives in association with humans, resulting in a positive

commensalism interaction. This fungus is a member of the normal human microbiota and colonizes the mucosal surface of gastrointestinal tract, vagina and the surface of humid skin (Yang, 2003; Fischer, 2012).

According to (Chaffin *et al.*, 1998), this delicate balance can be broken and start a parasitic relationship, resulting in an infection called candidiasis. Among the most important *C. albicans* virulence factors are the secretion of hydrolytic enzymes, morphological transition mechanisms (pleomorphism), antigenic variability and the immunomodulation of host defense mechanisms (Sturtevant and Calderone, 1997).

Currently, rats and mice are considered the most used animal as models to study candidiasis (Carrara *et al.*, 2010; Yano and Fidel, 2011). Fidel *et al.* (1993) established the following steps are necessary to the persistent vaginal infection development, which constitutes fungus penetration, tissue invasion, development and proliferation of this fungus in these animals and the estrogen treatment to induce a pseudo-estrus state. Rosymar Coutinho Lucas *et al.* / American Journal of Immunology 2016, 12 (2): 29.36 DOI: 10.3844/ajisp.2016.29.36



Fig. 3. Paraffin sections of mice vaginal tissue stained with toluidine blue, indicating mast degranulated: A, B, C and D = 4, 24, 48 and 192 h post-infection, respectively. E and F = uninfected controls, untreated and, treated with 0.02 mg of estrogen, respectively. Barr: 50 um



Fig. 4. PGE2 (pg/mL) detection in vaginal tissue of mice infected with *C. albicans*. Results represent the average of two measurement experiments using 5 animals for each infection time. One-way ANOVA, * p<0.001</p>

This differentiated hormonal system promotes the vaginal epithelium stratification and the keratin layer development that covers this epithelium, what is essential for the *C. albicans* attachment (Carrara *et al.*, 2010).



Fig. 5. IgE detection in vaginal tissue of mice infected with C. albicans. Results represent the optical density average of two measurement experiments using 5 animals for each infection time. One-way ANOVA,* p<0.001</p>

Another characteristic that shows the yeast invasive ability and the persistent infection establishment is the pleomorphism (Davies *et al.*, 1999). Many genes are associated to this feature and, in most cases, depend on the chemical and physical environmental conditions where the fungus is growing. Studies with *C. albicans* strains that had mutations in genes involved in the transition form, showed a reduction in virulence power, which had lost this characteristic (Calderone and Fonzi, 2001; Romani *et al.*, 2003).

According to the results shown in Fig. 1, the infected animals showed the hyphae and pseudo-hyphae morphology predominance, which supported the hypothesis that *C. albicans* invasion and fixation in the vaginal tissue depended on this morphological transition.

Micro-abscesses consisting mainly of polymorphonuclear cells were checked by hematoxylineosin staining in the mucosal layer (Fig. 2) prior to the infection time, however in some infection times detectable changes in the cellular pattern of the sub mucosal layer were observed, possibly due to lack of fungi invasion in deeper structures, which could lead to more effective and diversified cellular immune response (Black et al., 1998; de Bernardis et al., 2000). Yano et al. (2012) demonstrated an important polymorphonuclear role in the symptomatic VVC infection establishment, which seems to be related to alarmins production by the vaginal epithelial cells. These molecules are able to attract PMN and contribute to the acute VVC symptoms. However, the exactly immunological mechanism

involved in this response remains unclear. Other study showed that the PMN action on the vaginal tissue is responsible for the high infection levels, which provides tissue damage in VVC patients (Beghini *et al.*, 2012).

One proposed hypothesis to explain the vaginal candidiasis pathogenesis is the allergic response. *C. albicans* is able to induce the production of different antibodies classes, such as IgG, IgA and IgE. Some studies have demonstrated the IgE presence in serum and vaginal secretions in 87% of women with vaginal candidiasis (Witikin *et al.*, 1988; Regúlez *et al.*, 1994) increasing the premise that the immunoglobulin role in the vaginal candidiasis pathogenesis is associated to the histamine released by locally mast cells. Furthermore, histamine is able to locally induce the prostaglandin E2 production that may be responsible for the local immune response and immunomodulation process (Witikin *et al.*, 1988; Noverr *et al.*, 2001; Regúlez *et al.*, 1994).

Thus, PGE2 and IgE (Fig. 4 and 5) detection results showed an increase in the concentration of these mediators prior to infection times, which were more significant for PGE2, since its concentration was determined using a standard curve. No standard IgE curve was constructed and the results showed only a difference in absorbance between samples at 450 nm, which indirectly represents the difference in their concentrations. Analysis of tissues stained with toluidine blue showed increased mast cell previous to infection times (Fig. 3), which coincide with the IgE and PGE2 increase. These findings may explain the mechanisms involved in the vaginal tissue immune response and immune response associated to an allergic pattern.

It is recognized that symptomatic patients with frequent recurrences have higher IgE anti-*Candida* levels in vaginal contents than in normal or asymptomatic patients. The number of mast cells present in normal vaginal mucosa is small; however, it seems to be increased during the infection caused by some genera such as *Candida*, *Chlamydia* and *Trichomonas* (Witikin *et al.*, 1988).

Studies have shown that the increase in PGE2 during *C. albicans* infections may be associated with the fungus colonization, because it facilitates the yeast morphological transition to pseudohyphae, follow by Th1-type immune response inhibition, chemokine release, phagocytosis and lymphocyte proliferation, culminating in Th2 type immune response and tissue eosinophilia (Noverr *et al.*, 2001; 2002; Erb-Downward and Noverr, 2007; Kalo-Klein and Witkin, 1990).

According to (Barousse *et al.*, 2005) there is an important anti-*Candida* activity in epithelial cells, raising the hypothesis that the VVC susceptibility is associated to signs from vaginal epithelial cell interaction with *Candida*, which promotes clinical symptoms such as leukocyte inflammatory response, but no protective, while VVC resistance is associated to the lack of signs and/or

antifungal epithelial cells activity and absence of inflammation (Fidel, 2007; Jaeger *et al.*, 2013).

Treatment against *C. albicans* consists in use, in the most of time, "azoles", especially fluconazole to control the pathogen proliferation. In this case, these treatments don't affect directly the PMNs or mast cell migration and mediator secretion, but these drugs interfere on the development, affecting the biosynthesis of ergosterol. Thus, with the decrease of pathogen number, the local immune response decreases too, restoring the balance of the vaginal flora (Cassone, 2015).

However, in the few years there has been reported an increase of pathogen resistance to the antifungal treatment, some explanations by this increase is related especially to some genetics aspects of this yeast, such as modifications in its sterol biosynthesis pathway by the mutations or over expression of genes involved in this event, alteration of genes encoding efflux pumps of the drugs and also its transporters. Thus, due to these mechanisms already explained the pathogen population is always high, maintaining the local immune response high too, which explains the most of results obtained in this research (Sobel, 2016; Akins, 2005; Morschhäuser, 2002).

Conclusion

VVC is a public health problem with high occurrence rates that should be carefully monitored by the scientific community, in addition to the conventional therapies for the prevention of VVC which become obsolete, each year and do not prevent recurrence.

Thus, this research tried to elucidate some aspects of vaginal tissue physiology and immunological mechanisms involved in the VVC, opening new perspectives to future studies about cell signaling and host-parasite interaction in infectious processes, providing scientific basis for more effective prophylactic and therapeutic interventions against vaginal yeast infections.

Acknowledgement

We are thankful for the technical support from Marly de Castro, Deise Lúcia Chesca, Carlos Sorgi, Maria Dolores, Vani Alves and Auristela.

Funding Information

There was no specific financial support for this research.

Author Contributions

Rosymar Coutinho Lucas and Carol K. Da Fonseca: Design and development of the study.

Rodrigo A. Cazzaniga and Carolina Nunes França: Analysis of the results.

Fernando Segato, Rafael Taglialegna and Claudia M.L. Maffei: Development of the manuscript.

Conflict of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and the writing of the paper.

References

Akins, R.A., 2005. An update on antifungal targets and mechanisms of resistance in *Candidaalbicans*. Med. Mycol., 43: 285-318.

DOI: 10.1080/13693780500138971

Barousse, M.M., T. Espinosa, K. Dunlap and P.L.Jr. Fidel, 2005. Vaginal epithelial cell anti-*Candida albicans* activity is associated with protection against symptomatic vaginal candidiasis. Infect. Immun., 73: 7765-7767.

DOI: 10.1128/IAI.73.11.7765-7767.2005

Beghini, J., P.C. Giraldo, R. Riboldi, R.L. Amaral and J. Jr. Eleutério *et al.*, 2012. Altered CD16 expression on vaginal neutrophils from women with vaginitis. Eur. J. Obstet. Gynecol. Reprod. Bio., 167: 96-99. DOI: 10.1016/j.ejogrb.2012.11.008

Bennett, R.J. and A.D. Johnson, 2005. Mating in *Candida albicans* and the search for a sexual cycle. Annu. Rev. Microbiol., 59: 233-255. DOI: 10.1146/annurev.micro.59.030804.121310

- Black, C.A., F.M. Eyers, A. Russell, M.L. Dunkley and R.L. Clancy *et al.*, 1998. Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect. Immun., 66: 1273-1275.
- Calderone, R.A. and W.A. Fonzi, 2001. Virulence factors of *Candida albicans*. Trends Microbiol., 9: 327-335. DOI: 10.1016/S0966-842X(01)02094-7
- Carrara, M.A., L. Donaltti, E. Damke, T.I. Svidizinski and M.E. Consolaro *et al.*, 2010. A new model of vaginal infection by *Candida albicans* in rats. Mycopathologia, 170: 331-338. DOI: 10.1007/s11046-010-9326-1
- Cassone, A., 2015. Vulvovaginal Candida albicans infections: Pathogenesis, immunity and vaccine prospects, BJOG, 122: 785-94. DOI: 10.1111/1471-0528.12994
- Cassone, A., F. De Bernardis and G. Santoni, 2007. Anticandidal immunity and vaginitis: Novel opportunities for immune intervention. Infect. Immun., 75: 4675-4686. DOI: 10.1128/IAI.00083-07
- Chaffin, W.L., J.L. López-Ribot, M. Casanova, D. Gozalbo and J.P. Martinez, 1998. Cell wall and secreted proteins of *Candida albicans*: Identification, function and expression. Microbiol. Mol. Biol. Rev., 62: 130-180. PMID: 9529890

- Davies, J.M., A.J. Stacey and C.A. Gilligan, 1999. *Candida albicans* hyphal invasion: Thigmotropism or chemotropism?. FEMS Microbiol. Lett., 171: 245-249. DOI: 10.1111/j.1574-6968.1999.tb13439.x
- de Bernardis, F., G. Santoni, M. Boccanera, E. Spreghini and D. Adriani *et al.*, 2000. Local anticandidal immune responses in a rat model of vaginal infection by and protection against *Candida albicans*. Infect. Immun., 68: 3297-3304. DOI: 10.1128/IAI.68.6.3297-3304.2000
- Erb-Downward, J.R. and M.C. Noverr, 2007. Characterization of prostaglandin E2 production by *Candida albicans*. Infect. Immun., 75: 3498-3505.
- Fidel, P.L. Jr., 2007. History and update on host defense against vaginal candidiasis. Am. J. Reprod. Immunol., 57: 2-12. DOI: 10.1111/j.1600-0897.2006.00450
- Fidel, P.L. Jr., J.L. Cutright and J.D. Sobel, 1995. Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to *Candida albicans* infections. Infect. Immun., 63: 4191-4194.
- Fidel, P.L. Jr., M.E. Lynch and J.D. Sobel, 1993. Candidaspecific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect. Immun., 61: 1990-1995. PMID: 8097493
- Fischer, G., 2012. Chronic vulvovaginal candidiasis: What we know and what we have yet to learn. Aus. J. Dermatol., 53: 247-254.

DOI: 10.1111/j.1440-0960.2011.00860.x

- Gomori, G., 1950. A rapid one-step trichrome stain. Am. J. Clin. Path., 20: 661-664. PMID: 15432364
- Harriott, M.M., E.A. Lilly, T.E. Rodriguez, P.L. Jr. Fidel and M.C. Noverr, 2010. *Candida albicans* forms biofilms on the vaginal mucosa. Microbiology, 156: 3635-3644. DOI: 10.1099/mic.0.039354-0
- Jaeger, M., T.S. Plantinga, L.A. Joosten, B.J. Kullberg and M.G. Netea, 2013. Genetic basis for recurrent vulvo-vaginal candidiasis. Curr. Infect. Dis. Rep., 15: 136-142. DOI: 10.1007/s11908-013-0319-3
- Kalo-Klein, A. and S.S. Witkin, 1990. Prostaglandin E2 enhances and gamma interferon inhibits germ tube formation in *Candida albicans*. Infect. Immun., 58: 260-262. PMID: 2152888
- Lacaz, C.S., 2002. Tratado de Micologia Médica. 9th Edn., Sarvier, São Paulo, ISBN-10: 8573781238, pp: 1104.
- McCullough, M.J., B.C. Ross and P.C. Reade, 1996. *Candida albicans*: A review of its history, taxonomy, epidemiology, virulence attributes and methods of strain differentiation. Int. J. Oral Maxillofac. Surg., 25: 136-144. DOI: 10.1016/S0901-5027(96)80060-9
- Morschhäuser, J., 2002. The genetic basis of fluconazole resistance development in *Candida albicans*. Biochim. Biophys. Acta., 18: 240-248. PMID: 12084466

- Noverr, M.C., G.B. Toews and G.B. Huffnagle, 2002. Production of prostaglandins and leukotrienes by pathogenic fungi. Infect. Immun., 70: 400-402. DOI: 10.1128/IAI.70.1.400-402.2002
- Noverr, M.C., S.M. Phare, G.B. Toews, M.J. Coffey and G.B. Huffnagle, 2001. Pathogenic yeasts *Cryptococcus neoformans* and *Candida albicans* produce immunomodulatory prostaglandins. Infect. Immun., 69: 2957-2963.

DOI: 10.1128/IAI.69.5.2957-2963.2001

- Regúlez, P., J.F. García Fernández, M.D. Moragues, J. Schneider and G. Quindós *et al.*, 1994. Detection of anti-*Candida albicans* IgE antibodies in vaginal washes from patients with acute vulvovaginal candidiasis. Gynecol. Obstet. Invest., 37: 110-114. DOI: 10.1159/000292536
- Romani, L., F. Bistoni and P. Puccetti, 2003. Adaptation of *Candida albicans* to the host environment: The role of morphogenesis in virulence and survival in mammalian hosts. Curr. Opin. Microbiol., 6: 338-343. DOI: 10.1016/S1369-5274(03)00081-X
- Sobel, J.D., 2016. Recurrent vulvovaginal candidiasis. Am. J. Obstet. Gynecol., 214: 15-21. DOI: 10.1016/j.ajog.2015.06.067

- Sturtevant, J. and R. Calderone, 1997. *Candida albicans* adhesins: Biochemical aspects and virulence. Rev. Iberoam. Micol., 14: 90-97. PMID: 17655381
- Witikin, S.S., J. Jeremias and W.J. Ledger, 1988. A localized vaginal allergic response in women with recurrent vaginitis, J. Allergy Clin. Immunol., 81: 412-416. DOI: 10.1016/0091-6749(88)90909-8
- Yang, Y.L., 2003. Virulence factors of *Candida* species.J. Microbiol. Immunol. Infect., 36: 223-228.PMID: 14723249
- Yano, J. and P.L. Jr. Fidel, 2011. Protocols for vaginal inoculation and sample collection in the experimental mouse model of *Candida* vaginitis. J. Vis. Exp., 8: 3382-3382. PMID: 22215135
- Yano, J., J.K. Kolls, K.I. Happel, F. Wormley and K.L. Wozniak *et al.*, 2012. The acute neutrophil response mediated by S100 alarmins during vaginal *Candida* infections is independent of the Th17pathway. PLoS One, 7: 1-8. DOI: 10.1371/journal.pone.0046311